<DOC>
	<DOCNO>NCT01432561</DOCNO>
	<brief_summary>In order meet FDA standard safety efficacy report new drug , food-effect bioavailability ( impact presence food digestive tract rate extent drug absorb bloodstream deliver site action ) must collect . Cystagon™ FDA approve drug treatment rare disease cystinosis become available 1994 , inadequate knowledge food-effect drug 's bioavailability . This study aim investigate food affect absorption Cystagon™ bloodstream normal healthy adult .</brief_summary>
	<brief_title>Study Healthy Adults Determine Effect That Food Has Absorption Delivery Drug Cystagon™</brief_title>
	<detailed_description />
	<mesh_term>Cystinosis</mesh_term>
	<mesh_term>Fanconi Syndrome</mesh_term>
	<mesh_term>Cysteamine</mesh_term>
	<criteria>1 . Male female , smoker ( 25 cigarette daily ) nonsmoker , 18 year age old , BMI &gt; 18 &lt; 30.0 . 2 . Females childbearing potential sexually active must willing use two form contraceptive method throughout study 14days last study drug administration . 3 . Minimum weight 50 kg . 4 . Good health , define history chronic illness require regular medication/therapy . 5 . Must swallow tablet regular basis . 1 . Evidence Helicobacter pylorus infection , presently , within last year . 2 . Subjects know hypersensitivity cysteamine . 3 . History , currently within past 3 month , follow condition : Pancreatitis Inflammatory bowel disease Malabsorption Severe liver disease Unstable heart disease , e.g. , myocardial infarction , heart failure , arrhythmia . Unstable diabetes mellitus Any bleeding disorder . ZollingerEllison syndrome Malignant disease 4 . Subjects may pregnant health issue make unsafe participate , whose concomitant medical problem preclude commit study schedule . 5 . Use investigational drug within 30 day ( 90 day biologics ) prior dose . 6 . Use prescription medication within 14 day prior first dosing ; 7 . Use overthecounter product include natural health product ( e.g . food supplement herbal supplement ) within 7 day prior first dosing . 8 . Donation plasma within 7 day prior dose . Donation loss blood ( exclude volume drawn screen ) 50 mL 499 mL blood within 30 day , 499 mL within 56 day prior dose . 9 . Hemoglobin &lt; 13.5 g/dL ( male ) &lt; 12.0 g/dL ( female ) hematocrit &lt; 41.0 % ( male ) &lt; 36.0 % ( female ) screen . 10 . Breastfeeding subject . 11 . Immunization live attenuate vaccine 1 month prior dose plan vaccination course study . 12 . Presence fever ( body temperature &gt; 37.6°C ) ( e.g . fever associate symptomatic viral bacterial infection ) within 2 week prior dose .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>Lysosomal Storage Diseases</keyword>
	<keyword>Metabolic Diseases</keyword>
	<keyword>Metabolism , Inborn Errors</keyword>
</DOC>